Physician profile
Thomas C Kenkel
NPI 1558437624
$3,802.30
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $781 · 2020: $1,047 · 2021: $1,812 · 2022: $162.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $667.24 | 2019-2021 | |
| Fresenius USA Marketing, INC. | $571.40 | 2019-2022 | |
| Amgen INC. | $363.11 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $302.93 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $288.52 | 2020-2022 | |
| Vifor Pharma, INC. | $278.13 | 2019-2021 | |
| Akebia Therapeutics INC | $202.23 | 2019-2022 | |
| Daiichi Sankyo INC. | $188.79 | 2020-2021 | |
| Veloxis Pharmaceuticals, INC. | $145.09 | 2020-2021 | |
| Opko Pharmaceuticals, LLC | $142.78 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $84.30 | 2019-2021 | |
| Novo Nordisk INC | $66.94 | 2021 | |
| Glaxosmithkline, LLC. | $63.42 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.29 | 2020-2021 | |
| Genentech USA, INC. | $46.69 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $39.83 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $37.29 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.83 | 2021 | |
| Horizon Therapeutics Plc | $32.89 | 2019-2020 | |
| Allergan, INC. | $32.62 | 2019 | |
| Shire North American Group INC | $26.03 | 2019 | |
| Pharmacosmos Therapeutics INC. | $24.48 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $21.88 | 2021 | |
| Arbor Pharmaceuticals, INC. | $17.97 | 2020 | |
| Medtronic, INC. | $15.83 | 2021 | |
| Aurinia Pharma U.S., INC. | $15.40 | 2021 | |
| Abbvie INC. | $15.12 | 2021 | |
| W. L. Gore & Associates, INC. | $13.27 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Kenkel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.